Vor Biopharma (VOR) Shares Outstanding (Weighted Average) (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $43.0 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $43.0 million, up 589.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.0 million (up 589.15% YoY), and the FY2025 annual result was $9.9 million, up 187.35% from the prior year.
• Shares Outstanding (Weighted Average) advanced to $43.0 million in Q1 2026 per VOR's latest filing, from $9.9 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $125.3 million in Q2 2025 and troughed at $3.4 million in Q3 2024.
• A 5-year average of $44.3 million and a median of $39.6 million in 2022 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Weighted Average) plunged 94.9% in 2024, then jumped 589.15% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $39.6 million in 2022, then soared by 69.89% to $67.2 million in 2023, then slumped by 94.89% to $3.4 million in 2024, then jumped by 187.35% to $9.9 million in 2025, then jumped by 335.7% to $43.0 million in 2026.
• Business Quant data shows VOR's Shares Outstanding (Weighted Average) at $43.0 million in Q1 2026, $9.9 million in Q4 2025, and $6.4 million in Q3 2025.